Search results - 9 results
Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.
meta-analysis to assess the prevalence of genital HPV infection in the general male population. We searched Embase, Ovid MEDLINE, and the Global Index Medicus for studies published between Jan 1, 1995, and June ...
Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management.
screening population. The primary outcome will be to assess the diagnostic test accuracy of host and HPV DNA methylation for high-grade CIN; the secondary outcomes will be to examine the accuracy of different ...
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
Cervical Dysplasia Uterine Cervical Neoplasms Abstract: AIM: The Papilloplex high-risk human papillomavirus (hrHPV) test (Genefirst, Oxford, UK) is a single tube real-time HPV test which provides multiplex ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Guidelines as Topic Reproducibility of Results Sensitivity and Specificity Uterine Cervical Neoplasms Abstract: BACKGROUND Cervical cancer screening with assays detecting DNA of high-risk human papillomavirus ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
provided by colposcopy combined with histological assessment of biopsies. RESULTS: A first VALHUDES study has started in Belgium in December 2017 with enrolment from four colposcopy centres. The following ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
assessment, we considered it as high-risk (hr) HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and ...
Early effects of human papillomavirus vaccination in Belgium.
vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age ...
Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening.
quality assessments) for high-risk HPV detection in cervicovaginal samples using a molecular method — but not for cytopathology — is mandatory for reimbursement. The use of colposcopies in Belgium, with ...
Chapter 10: HPV testing on cervical cancer specimens: which assay can be used in cervical cancer screening.
screening programmes need to know which HPV tests are credible and have evidence-based performance in primary screening. Systematic reviews have assessed which high-risk HPV DNA tests are sufficiently ...